Form 4: ASMB CEO Okazaki Receives Equity Grant, Vesting Set

Assembly Biosciences CEO Jason Okazaki was granted 94,250 restricted stock units, with a portion contingent on shareholder approval of a plan amendment.

Summary

• Jason A. Okazaki, CEO and President, and a Director of Assembly Biosciences, Inc. (ASMB), was granted 94,250 restricted stock units (RSUs).
• The RSUs represent 65% of Mr. Okazaki's annual equity grant.
• The remaining 35% of the annual equity grant is contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan, which would increase the number of shares authorized for issuance.
• The granted RSUs will vest in four approximately equal installments on March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, subject to continuous service.
• Following this transaction, Mr. Okazaki beneficially owns 111,916 shares of common stock.
• This total includes 2,909 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan on May 14, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation and retention efforts, which are generally favorable for corporate stability and long-term alignment.

Positives

• The grant of restricted stock units to the CEO indicates a commitment to executive retention and aligns management's interests with long-term shareholder value.
• The equity grant is a standard component of executive compensation, reflecting ongoing confidence in the CEO's leadership.

Negatives

• No explicit negatives are detailed in this Form 4 filing, which primarily reports an executive compensation event.

Risks

• A portion (35%) of the CEO's annual equity grant is contingent on shareholder approval of an amendment to the 2018 Stock Incentive Plan, which, if not approved, could impact the full intended compensation.

Future Outlook

The future outlook includes the vesting of the granted RSUs over the next four years, contingent on the CEO's continuous service. Additionally, a portion of the annual equity grant is subject to future shareholder approval of an amendment to the company's 2018 Stock Incentive Plan.

Management Comments

• The grant of restricted stock units to Jason A. Okazaki, CEO and President, is part of his annual equity compensation.

Industry Context

StockSavvy.ai notes that executive equity grants, such as restricted stock units, are a standard practice across the biotechnology and pharmaceutical industries. These grants are crucial for attracting, retaining, and motivating key leadership, aligning their long-term incentives with shareholder returns. The structure of vesting over several years is typical for ensuring executive commitment.

Comparison to Industry Standards

• The grant of RSUs as a significant component of executive compensation is consistent with practices observed in comparable biotech companies, where equity often forms a substantial part of total remuneration.
• The four-year vesting schedule is a common industry standard designed to promote long-term executive retention and performance, similar to plans at companies like Moderna or BioNTech for their senior executives.

Corporate Governance

Related Party Transactions

• The grant of 94,250 restricted stock units to Jason A. Okazaki, the CEO and President, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Will be asked to approve an amendment to the 2018 Stock Incentive Plan, which could dilute existing shares but is necessary for executive compensation and retention.
• Employees (including CEO): The CEO benefits directly from the equity grant, aligning his interests with the company's long-term performance. The Employee Stock Purchase Plan also benefits participating employees.

Next Steps

• Shareholders will need to vote on an amendment to the 2018 Stock Incentive Plan to increase authorized shares, which will determine if the remaining 35% of the CEO's annual equity grant is issued.
• The granted RSUs will vest in installments on March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, assuming continuous service.

Key Dates

Recommendation

The filing details a routine executive equity grant, which is a standard component of compensation and retention for publicly traded companies. It does not introduce new material information that would significantly alter the company's fundamental valuation or warrant a change in investment thesis. Investors should consider this as part of ongoing operational costs and executive alignment.

Keywords

Form 4, Restricted Stock Units, RSU, Equity Grant, Insider Transaction, Executive Compensation, CEO, Assembly Biosciences, ASMB, Stock Incentive Plan, Corporate Governance